Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

"Cellceutix currently is evaluating Kevetrin in an open-label, dose-escalation Phase 2a trial in Platinum-Resistant/Refractory Ovarian Cancer. Patients will receive more frequent dosing (three times per week) at higher starting levels (250 mg/m2) and will be subsequently followed while under standard of care cancer treatment. The estimated primary completion date for the study is December 31, 2017."

https://clinicaltrials.gov/ct2/show/NCT03042702

A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Cellceutix Corporation
Sponsor:
Cellceutix Corporation
Information provided by (Responsible Party):
Cellceutix Corporation
ClinicalTrials.gov Identifier:
NCT03042702
First received: February 1, 2017
Last updated: February 17, 2017
Last verified: February 2017